is entering human trials on amyotrophic lateral sclerosis (ALS) with a uniquely powerful personalized medicine solution and is able to help with other diseases - such as stroke, brain trauma, Parkinson's, diabetes - to ophthalmology, orthopedic and cosmetic applications. Leveraging their semiconductor platform they bring major cost and automation benefits into stem cell therapy.

NeuroSyntek technology allows for autologous mono-phenotype stem-cells cultures to be screened, grown and differentiated for transplantation without the risk of transformation into tumors. They enable this revolutionary approach through the use of their proprietary StemOptimizer platform and behavioral models. This powerful combination allows for unprecedented control over the cellular behavior, in vitro, for precise, automated and continuous cell culture monitoring and manipulation.

The StemOptimizer is build around an advanced System-on-Chip architecture and their proprietary silicon extra-cellular sensor. This design allows for an adaptive, dynamically reconfigurable, and able to learn architecture that is the anchor for their aggressive and broad-based product roadmap.

Their disruptive technology will help to optimize the massively inefficient $6 trillion healthcare market by dramatically driving down costs and providing effective solutions for stem-cell therapies. In Phase I of their product roadmap they are addressing the $30B+ stem cells market.